startups to watch

Rice Alliance event identifies 4 most-promising energy tech companies at CERAWeek

CERAWeek attendees identified the four energy tech companies to watch. Photo via Getty Images

Wondering what energy tech companies you should keep an eye on? Wonder no more.

As a part of 2021 CERAWeek by IHS Markit, the Rice Alliance for Technology and Entrepreneurship hosted a virtual pitch competition today featuring 20 companies in four sessions. Each entrepreneur had four minutes to pitch, and then a few more to take questions from industry experts.

"Of the companies here today, we've intentionally selected a diverse group," says Brad Burke, managing director of the Rice Alliance at the start of the event. "They range from companies looking for their seed funding to companies that have raised $20 million or more."

The following companies pitched at the event: Acoustic Wells, ALLY ENERGY, Bluefield Technologies, Cemvita Factory, Connectus Global, Damorphe, Ovopod Ltd., DrillDocs, GreenFire Energy, inerG, Locus Bio-Energy Solutions, Nesh, Pythias Analytics, REVOLUTION Turbine Technologies, Revterra, ROCSOLE, Senslytics, Subsea Micropiles, Syzygy Plasmonics, Transitional Energy, and Universal Subsea.

At the end of each session, attendees voted via Zoom poll on which startup had the most potential. According to the event attendees, the most promising energy tech companies are:

REVOLUTION Turbine Technologies

Asheville, North Carolina-based REVOLUTION Turbine Technologies, an inaugural Greentown Houston member company, is working to "put a green spin on power." The company's micro-Expansion Turbine System produces green power for digital oilfield and pipeline initiatives through the recovery of excess natural gas pressure.

"RTT's technology provides a scalable, clean energy source to reliably power digital oilfield and pipeline initiatives at a significantly low operating cost," says Christopher Bean, founder and CEO, in his presentation. "Never has it been more important to make production and pipeline operations greener, safer, and efficient."

Connectus Global

Connectus Global, based in Calgary, provides custom technology solutions that can increase productivity, profits, and competitiveness. Connectus' Real-Time Location System, or RTLS, uses Ultra-Wide Band for communication and triangulation while hosting a Radio Frequency Identification Device, which come in the form of badges, tags, and receivers.

"In our first year, we received $800,000 in revenue and are on track to hit our numbers — $3.6 million — at the end of this fiscal year," says Mike Anderson, CEO of the company, in his presentation." We have a global white labeling agreement with Honeywell and we make up about 75 percent of their digitized workforce management portfolio."

The company's U.S. office is located in Houston.

DrillDocs

Houston-based DrillDocs has created an automated drilling cuttings characterization service, called CleanSight, that supports an operator's understanding of their wellbore's state of stability and cleanness in real time.

"We're taking computer vision to the drilling rig," says Calvin Holt, CEO and co-founder at DrillDocs, in his presentation. "Now for the first time, drilling and geomechanics teams will have unique, real-time data to ascertain the well's condition."

Revterra

Revterra, a Houston-based company and inaugural Greentown Houston member company, is creating a flywheel energy storage system for long-duration grid-scale applications.

"For those of us in Texas, the power outages we experienced a couple weeks ago are a stark reminder that the stability and the resiliency of our electric grid should be a top priority as we transition to low-emission power sources," says Ben Jawdat, founder and CEO at Revterra, in his presentation. "Energy storage is a critical element in both grid stability and enabling our transition to sustainable energy."

Trending News

Building Houston

 
 

Tvardi Therapeutics Inc. has fresh funds to support its drug's advancement in clinical trials. Photo via Getty Images

A Houston-based clinical-stage biopharmaceutical company has raised millions in its latest round.

Tvardi Therapeutics Inc. closed its $74 million series B funding round led by new investors New York-based Slate Path Capital, Florida-based Palkon Capital, Denver-based ArrowMark Partners, and New York-based 683 Capital, with continued support and participation by existing investors, including Houston-based Sporos Bioventures.

"We are thrilled to move out of stealth mode and partner with this lineup of long-term institutional investors," says Imran Alibhai, CEO at Tvardi. "With this financing we are positioned to advance the clinical development of our small molecule inhibitors of STAT3 into mid-stage trials as well as grow our team."

Through Slate Path Capital's investment, Jamie McNab, partner at the firm, will join Tvardi's board of directors.

"Tvardi is the leader in the field of STAT3 biology and has compelling proof of concept clinical data," McNab says in the release. "I look forward to partnering with the management team to advance Tvardi's mission to develop a new class of breakthrough medicines for cancer, chronic inflammation, and fibrosis."

Tvardi's latest fundraise will go toward supporting the company's products in their mid-stage trials for cancer and fibrosis. According to the release, Tvardi's lead product, TTI-101, is being studied in a Phase 1 trial of patients with advanced solid tumors who have failed all lines of therapy. So far, the drug has been well-received and shown multiple durable radiographic objective responses in the cancer patients treated.

Dr. Keith Flaherty, who is a member of Tvardi's scientific advisory board and professor of medicine at Harvard Medical School, offered his support of the company.

"STAT3 is a compelling and validated target. Beyond its clinical activity, Tvardi's lead molecule, TTI-101, has demonstrated direct downregulation of STAT3 in patients," he says in the release. "As a physician, I am eager to see the potential of Tvardi's molecules in diseases of high unmet medical need where STAT3 is a key driver."

Trending News